Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 11/2012

01-11-2012 | Brief Report

Molecular analysis of the mutational effects of Thai street rabies virus with increased virulence in mice after passages in the BHK cell line

Authors: Phatthamon Virojanapirom, Pakamatz Khawplod, Artikaya Sawangvaree, Supaporn Wacharapluesadee, Thiravat Hemachudha, Kentaro Yamada, Kinjiro Morimoto, Akira Nishizono

Published in: Archives of Virology | Issue 11/2012

Login to get access

Abstract

QS-BHK-P7, street rabies virus, after passages in the BHK cell line, had an in vitro phenotype that distinguished it from its parental virus. Both viruses caused lethal infection in mice by central nervous system inoculation; however, only QS-BHK-P7 killed mice by the intramuscular route. We found four mutations, S23R and H424P in ectodomain of the glycoprotein (G), I1711 V in the polymerase genes, and another at the non-coding region between the phosphoprotein and matrix protein genes of QS-BHK-P7. None of the mutations in the G gene occurred in previously reported pathogenic determinants. The roles of mutations in particular non-coding regions remain to be elucidated.
Literature
1.
Hemachudha T, Laothamatas J, Rupprecht CE (2002) Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 1(2):101–109PubMedCrossRef
2.
Wunner WH (2007) Rabies virus. In: Jackson A, Wunner WH (eds) Rabies, 2nd edn. Elsevier, San Diego, pp 23–68CrossRef
3.
Albertini AA, Ruigrok RW, Blondel D (2011) Rabies virus transcription and replication. Adv Virus Res 79:1–22PubMedCrossRef
4.
5.
Morimoto K, Hooper DC, Carbaugh H, Fu ZF, Koprowski H, Dietzschold B (1998) Rabies virus quasispecies: implications for pathogenesis. Proc Natl Acad Sci USA 95(6):3152–3156PubMedCrossRef
6.
Vos A, Neubert A, Aylan O, Schuster P, Pommerening E, Muller T, Chivatsi DC (1999) An update on safety studies of SAD B19 rabies virus vaccine in target and non-target species. Epidemiol Infect 123(1):165–175PubMedCrossRef
7.
Wu X, Smith TG, Rupprecht CE (2011) From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev Vaccines 10(11):1597–1608PubMedCrossRef
8.
Sakamoto S, Ide T, Nakatake H, Tokiyoshi S, Yamamoto M, Kawai A, Smith JS (1994) Studies on the antigenicity and nucleotide sequence of the rabies virus Nishigahara strain, a current seed strain used for dog vaccine production in Japan. Virus Genes 8(1):35–46PubMedCrossRef
9.
Mita T, Shimizu K, Ito N, Yamada K, Ito Y, Sugiyama M, Minamoto N (2008) Amino acid at position 95 of the matrix protein is a cytopathic determinant of rabies virus. Virus Res 137(1):33–39PubMedCrossRef
10.
Khawplod P, Shoji Y, Ubol S, Mitmoonpitak C, Wilde H, Nishizono A, Kurane I, Morimoto K (2006) Genetic analysis of dog rabies viruses circulating in Bangkok. Infect Genet Evol 6(3):235–240PubMedCrossRef
11.
Prehaud C, Wolff N, Terrien E, Lafage M, Megret F, Babault N, Cordier F, Tan GS, Maitrepierre E, Menager P, Chopy D, Hoos S, England P, Delepierre M, Schnell MJ, Buc H, Lafon M (2010) Attenuation of rabies virulence: takeover by the cytoplasmic domain of its envelope protein. Sci Signal 3(105):ra5
12.
Schnell MJ, McGettigan JP, Wirblich C, Papaneri A (2010) The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol 8(1):51–61PubMed
13.
Grdzelishvili VZ, Smallwood S, Tower D, Hall RL, Hunt DM, Moyer SA (2005) A single amino acid change in the L-polymerase protein of vesicular stomatitis virus completely abolishes viral mRNA cap methylation. J Virol 79(12):7327–7337PubMedCrossRef
14.
Grdzelishvili VZ, Smallwood S, Tower D, Hall RL, Hunt DM, Moyer SA (2006) Identification of a new region in the vesicular stomatitis virus L polymerase protein which is essential for mRNA cap methylation. Virology 350(2):394–405PubMedCrossRef
15.
Smallwood S, Easson CD, Feller JA, Horikami SM, Moyer SA (1999) Mutations in conserved domain II of the large (L) subunit of the Sendai virus RNA polymerase abolish RNA synthesis. Virology 262(2):375–383PubMedCrossRef
16.
Schnell MJ, Conzelmann KK (1995) Polymerase activity of in vitro mutated rabies virus L protein. Virology 214(2):522–530PubMedCrossRef
17.
Faber M, Pulmanausahakul R, Nagao K, Prosniak M, Rice AB, Koprowski H, Schnell MJ, Dietzschold B (2004) Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc Natl Acad Sci USA 101(46):16328–16332PubMedCrossRef
18.
Beckert A, Geue L, Vos A, Neubert A, Freuling C, Muller T (2009) Genetic stability (in vivo) of the attenuated oral rabies virus vaccine SAD B19. Microbiol Immunol 53(1):16–21PubMedCrossRef
19.
Finke S, Cox JH, Conzelmann KK (2000) Differential transcription attenuation of rabies virus genes by intergenic regions: generation of recombinant viruses overexpressing the polymerase gene. J Virol 74(16):7261–7269PubMedCrossRef
20.
21.
Stillman EA, Whitt MA (1997) Mutational analyses of the intergenic dinucleotide and the transcriptional start sequence of vesicular stomatitis virus (VSV) define sequences required for efficient termination and initiation of VSV transcripts. J Virol 71(3):2127–2137PubMed
22.
Hwang LN, Englund N, Pattnaik AK (1998) Polyadenylation of vesicular stomatitis virus mRNA dictates efficient transcription termination at the intercistronic gene junctions. J Virol 72(3):1805–1813PubMed
23.
Barr JN, Whelan SP, Wertz GW (1997) cis-Acting signals involved in termination of vesicular stomatitis virus mRNA synthesis include the conserved AUAC and the U7 signal for polyadenylation. J Virol 71(11):8718–8725PubMed
24.
Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP (2009) Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis 200(8):1251–1260PubMedCrossRef
25.
Finke S, Mueller-Waldeck R, Conzelmann KK (2003) Rabies virus matrix protein regulates the balance of virus transcription and replication. J Gen Virol 84(Pt 6):1613–1621PubMedCrossRef
26.
Masatani T, Ito N, Shimizu K, Ito Y, Nakagawa K, Sawaki Y, Koyama H, Sugiyama M (2010) Rabies virus nucleoprotein functions to evade activation of the RIG-I-mediated antiviral response. J Virol 84(8):4002–4012PubMedCrossRef
27.
Masatani T, Ito N, Shimizu K, Ito Y, Nakagawa K, Abe M, Yamaoka S, Sugiyama M (2010) Amino acids at positions 273 and 394 in rabies virus nucleoprotein are important for both evasion of host RIG-I-mediated antiviral response and pathogenicity. Virus Res 155(1):168–174PubMedCrossRef
28.
Shoji Y, Inoue S, Nakamichi K, Kurane I, Sakai T, Morimoto K (2004) Generation and characterization of P gene-deficient rabies virus. Virology 318(1):295–305PubMedCrossRef
29.
30.
Pulmanausahakul R, Li J, Schnell MJ, Dietzschold B (2008) The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread. J Virol 82(5):2330–2338PubMedCrossRef
31.
Wang ZW, Sarmento L, Wang Y, Li XQ, Dhingra V, Tseggai T, Jiang B, Fu ZF (2005) Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system. J Virol 79(19):12554–12565PubMedCrossRef
32.
Faber M, Faber ML, Li J, Preuss MA, Schnell MJ, Dietzschold B (2007) Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus. J Virol 81(13):7041–7047PubMedCrossRef
33.
Wirblich C, Schnell MJ (2011) Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. J Virol 85(2):697–704PubMedCrossRef
34.
Javier RT, Rice AP (2011) Emerging Theme: Cellular PDZ proteins as common targets of pathogenic viruses. J Virol 85(22):11544–11556PubMedCrossRef
Metadata
Title
Molecular analysis of the mutational effects of Thai street rabies virus with increased virulence in mice after passages in the BHK cell line
Authors
Phatthamon Virojanapirom
Pakamatz Khawplod
Artikaya Sawangvaree
Supaporn Wacharapluesadee
Thiravat Hemachudha
Kentaro Yamada
Kinjiro Morimoto
Akira Nishizono
Publication date
01-11-2012
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 11/2012
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-012-1402-z

Other articles of this Issue 11/2012

Archives of Virology 11/2012 Go to the issue

Original Article

Establishment and maintenance of persistent infection by picobirnavirus in greater rhea (Rhea Americana)

Original Article

Quantitative comparison of the RNA bacteriophage Qβ infection cycle in rich and minimal media

Erratum

Erratum to: An overview of infectious bursal disease

Brief Report

Experimental infection of laboratory-bred bank voles (Myodes glareolus) with murid herpesvirus 4

Original Article

Population dynamics of DENV-1 genotype V in Brazil is characterized by co-circulation and strain/lineage replacement

Original Article

Higher dN/dS ratios in the HCV core gene, but not in the E1/HVR1 gene, are associated with human immunodeficiency virus-associated immunosuppression
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits